...
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.
【24h】

Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.

机译:射频消融过程中低温敏感脂质体给药的数学时空模型。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Studies have demonstrated a synergistic effect between hyperthermia and chemotherapy, and clinical trials in image-guided drug delivery combine high-temperature thermal therapy (ablation) with chemotherapy agents released in the heating zone via low temperature sensitive liposomes (LTSL). The complex interplay between heat-based cancer treatments such as thermal ablation and chemotherapy may require computational models to identify the relationship between heat exposure and pharmacokinetics in order to optimise drug delivery. MATERIALS AND METHODS: Spatio-temporal data on tissue temperature and perfusion from heat-transfer models of radiofrequency ablation were used as input data. A spatio-temporal multi-compartmental pharmacokinetic model was built to describe the release of doxorubicin (DOX) from LTSL into the tumour plasma space, and subsequent transport into the extracellular space, and the cells. Systemic plasma and tissue compartments were also included. We compared standard chemotherapy (free-DOX) to LTSL-DOX administered as bolus at a dose of 0.7 mg/kg body weight. RESULTS: Modelling LTSL-DOX treatment resulted in tumour tissue drug concentration of approximately 9.3 microg/g with highest values within 1 cm outside the ablation zone boundary. Free-DOX treatment produced comparably uniform tissue drug concentrations of approximately 3.0 microg/g. Administration of free-DOX resulted in a considerably higher peak level of drug concentration in the systemic plasma compartment (16.1 microg/g) compared to LTSL-DOX (4.4 microg/g). These results correlate well with a prior in vivo study. CONCLUSIONS: Combination of LTSL-DOX with thermal ablation allows localised drug delivery with higher tumour tissue concentrations than conventional chemotherapy. Our model may facilitate drug delivery optimisation via investigation of the interplays among liposome properties, tumour perfusion, and heating regimen.
机译:目的:研究表明,热疗和化学疗法之间具有协同作用,图像引导药物递送的临床试验将高温热疗法(消融)与通过低温敏感脂质体(LTSL)在加热区释放的化学疗法药物结合在一起。基于热的癌症治疗(例如热消融和化学疗法)之间复杂的相互作用可能需要计算模型来识别热暴露和药代动力学之间的关系,以便优化药物的递送。材料与方法:射频消融传热模型的组织温度和灌注时空数据用作输入数据。建立了一个时空多室药代动力学模型来描述阿霉素(DOX)从LTSL释放到肿瘤血浆空间中,然后转运到细胞外空间和细胞中。全身血浆和组织隔室也包括在内。我们将标准化疗(游离DOX)与以剂量0.7 mg / kg体重推注的LTSL-DOX进行了比较。结果:对LTSL-DOX治疗进行建模,得出肿瘤组织药物浓度约为9.3微克/克,最高值在消融区边界外1厘米内。 Free-DOX处理可产生相对均匀的组织药物浓度,约为3.0 microg / g。与LTSL-DOX(4.4 microg / g)相比,游离DOX的给药在全身血浆区室中的药物浓度峰值水平(16.1 microg / g)明显更高。这些结果与先前的体内研究很好地相关。结论:LTSL-DOX与热消融相结合可使局部给药的肿瘤组织浓度高于常规化疗。我们的模型可以通过研究脂质体特性,肿瘤灌注和加热方案之间的相互作用来促进药物递送的优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号